Valion Bio says AFRRI, NIAID design murine survival protocol to test Entolimod for GI-ARS

Valion Bio, Inc.

Valion Bio, Inc.

VBIO

0.00
  • Valion Bio reported AFRRI and NIAID finalized a survival-efficacy protocol to evaluate Entolimod for gastrointestinal acute radiation syndrome.
  • Results have not been presented; the study is positioned to generate future non-clinical efficacy data to support a potential FDA Animal Rule filing.
  • The protocol uses a validated animal model intended to isolate GI injury, aiming to clarify whether Entolimod can improve survival outcomes.
  • The company framed the milestone as a step toward a first-in-class option in a market with no FDA-approved GI-ARS treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606250745PR_NEWS_USPR_____CL91855) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.